Skip to main content

CureVac Headquarters


Headquarters : Friedrich-Miescher-Str. 15th, 72076 Tuebingen, Germany
T +49 7071 9883 - 0
F +49 7071 9883 - 1101

Clinical Development : Schumannstrasse 27, 60325 Frankfurt, Germany
T +49 69 7680 587 - 0
F +49 69 7680 587 - 2222

USA : 250 Summer St 3rd Fl, Boston, MA 02210, USA

We are pioneering the development of a completely new class of drugs based on the messenger RNA (mRNA) molecule. The basic principle is the use of this molecule as a data carrier for information, with the help of which the body can produce its own active ingredients for fighting various diseases.

It all started with an unexpected discovery. CureVacs founder, Dr. Ingmar Hoerr, found out as a doctoral student that the unstable biomolecule mRNA can be used as a therapeutic vaccine or active ingredient when administered directly into the tissue if it is optimized beforehand. No complicated formulations or molecular modifications are necessary. With the help of this radical discovery, scientists can use the full potential of the mRNA molecule, which occurs in every human being, and thus change biomedical research in the long term.

We developed CureVac from the building blocks of life
As a pioneer, CureVac discovered the potential of mRNA for the treatment of diseases and for the manufacture of vaccines. Founded in 2000, CureVac is the first in the world to successfully use mRNA for medical purposes - where others once saw obstacles, we discovered opportunities. Today we are more than 450 employees who are passionate about unlocking the clinical potential of our proprietary mRNA technology. We want to offer tailor-made therapies for those patients who need them most.